EVAX
Evaxion·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Growth
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EVAX
Evaxion A/S
A clinical-stage biotech company developing AI-powered immunotherapies
Pharmaceutical
08/11/2008
02/05/2021
NASDAQ Stock Exchange
46
12-31
Depository Receipts (Ordinary Shares)
Dr. Neergaards Vej 5f DK-2970 Hoersholm, Denmark
--
Evaxion A/S was established on August 11, 2008 under the laws of the Kingdom of Denmark. The Company is a clinical-stage company that leverages its proprietary artificial intelligence or AI, technology, engineering expertise and drug development knowledge to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.
Earnings Call
Q1/2025
Estimate EPS-0.7
Actual EPS-0.01
Estimate Revenue60.00K
Actual Revenue0
Contradictions Revealed: Insights from the 2025 Q1 Earnings Call on EVX-B2 Development and ERV Vaccine Strategy
May 27,2025 10:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EVAX has released its 2025 Q2 earnings. EPS was reported at -0.02, versus the expected -0.58, beating expectations. The chart below visualizes how EVAX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EVAX has released its 2025 Q3 earnings report, with revenue of 7.49M, reflecting a YoY change of 148.33%, and net profit of 4.62M, showing a YoY change of 338.66%. The Sankey diagram below clearly presents EVAX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
